NCT02255760 - Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 4, 2014

Primary Completion Date

April 20, 2015

Study Completion Date

April 20, 2015

Conditions

MEDI3902 for Prevention of P. Aeruginosa Pneumonia

Interventions

DRUG

MEDI3902 - Dose 1

Participants will receive a single IV dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.

DRUG

MEDI3902 - Dose 2

Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.

DRUG

MEDI3902 - Dose 3

Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.

DRUG

MEDI3902 - Dose 4

Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.

OTHER

Placebo

Participants will receive a single dose of placebo by IV infusion up to a maximum of 12 hours.

Trial Locations (1)

Research Site, South Miami